Ginny Xiaohe Li, Lijun Chen, Yi Hsiao, Rahul Mannan, Yuping Zhang, Jie Luo, Francesca Petralia, Hanbyul Cho, Noshad Hosseini, Felipe da Veiga Leprevost, Anna Calinawan, Yize Li, Shankara Anand, Aniket Dagar, Yifat Geffen, Chandan Kumar-Sinha, Seema Chugh, Anne Le, Sean Ponce, Shenghao Guo, Cissy Zhang, Michael Schnaubelt, Nataly Naser Al Deen, Feng Chen, Wagma Caravan, Andrew Houston, Alex Hopkins, Chelsea J Newton, Xiaoming Wang, Daniel A Polasky, Sarah Haynes, Fengchao Yu, Xiaojun Jing, Siqi Chen, Ana I Robles, Mehdi Mesri, Mathangi Thiagarajan, Eunkyung An, Gad A Getz, W Marston Linehan, Galen Hostetter, Scott D Jewell, Daniel W Chan, Pei Wang, Gilbert S Omenn, Rohit Mehra, Christopher J Ricketts, Li Ding, Arul M Chinnaiyan, Marcin P Cieslik, Saravana M Dhanasekaran, Hui Zhang, Alexey I Nesvizhskii
Non-clear cell renal cell carcinomas (non-ccRCCs) encompass diverse malignant and benign tumors. Refinement of differential diagnosis biomarkers, markers for early prognosis of aggressive disease, and therapeutic targets to complement immunotherapy are current clinical needs. Multi-omics analyses of 48 non-ccRCCs compared with 103 ccRCCs reveal proteogenomic, phosphorylation, glycosylation, and metabolic aberrations in RCC subtypes. RCCs with high genome instability display overexpression of IGF2BP3 and PYCR1...
April 26, 2024: Cell reports medicine